ETPrime

Bliss GVS Pharma Share Price

  • 111.84-0.23 (-0.21%)
  • Volume: 2,35,045
  • Closed
  • Last Updated On: 09 May, 2025, 03:31 PM IST
STOCK SCORE
ETPrime Only
  • 1D
  • 1W
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Loading...
Bliss GVS Pharma Share Price
  • 111.84-0.23 (-0.21%)
  • Volume: 2,35,045
Advertisment

Bliss GVS Pharma share price insights

  • Meeting Agenda: Audited Results & Final Dividend. Please add to watchlist to track closely.

  • Company has spent less than 1% of its operating revenues towards interest expenses and 12.41% towards employee cost in the year ending Mar 31, 2024. (Source: Consolidated Financials)

  • Bliss GVS Pharma Ltd. share price moved down by -0.21% from its previous close of Rs 112.07. Bliss GVS Pharma Ltd. stock last traded price is 111.84

    Share PriceValue
    Today/Current/Last111.84
    Previous Day112.07111.30

InsightsBliss GVS Pharma

    Do you find these insights useful?

    • hate it

    • meh

    • love it

    Key Metrics

    PE Ratio
    (x)    		19.77
    EPS - TTM
    (₹)    		5.66
    MCap
    (₹ Cr.)    		1,178.46
    Sectoral MCap Rank
    		74
    PB Ratio
    (x)    		1.18
    Div Yield
    (%)    		0.45
    Face Value
    (₹)    		1.00
    Beta

    Beta

    1 Month1.25
    3 Months0.50
    6 Months0.82
    1 Year0.87
    3 Years1.09

    		1.25
    VWAP
    (₹)    		110.62
    52W H/L
    (₹)
    185.50 / 92.15

    Bliss GVS Pharma Share Price Returns

    1 Day-0.21%
    1 Week-5.16%
    1 Month-3.93%
    3 Months-25.12%
    1 Year1.4%
    3 Years49.22%
    5 Years17.23%

    ET Stock ScreenersTop Score Companies

    Check whether Bliss GVS Pharma belongs to analysts' top-rated companies list?

    View Stock Screeners

    Bliss GVS Pharma News & Analysis

    View all Bliss GVS Pharma Share News & Announcements

    Bliss GVS Pharma Share Analysis

    Unlock Stock Score, Analyst' Ratings & Recommendations

    Share Analysis Non Prime User
    • View Stock Score on a 10-point scale
    • See ratings on Earning, Fundamentals, Valuation, Risk & Price
    • Check stock performance
    JOIN ET PRIME

    Bliss GVS Pharma Share Recommendations

    • Target₹214
    • OrganizationIndependent Analyst
    • BUY
    • Target₹220
    • OrganizationIndependent Analyst
    • BUY

    That's all for Bliss GVS Pharma recommendations. Check out other stock recos.

    Bliss GVS Pharma Financials

    • Insights

      • Employee & Interest Expense

        Company has spent less than 1% of its operating revenues towards interest expenses and 12.41% towards employee cost in the year ending Mar 31, 2024. (Source: Consolidated Financials)
      Quarterly | AnnualDec 2024Sep 2024Jun 2024Mar 2024Dec 2023
      Total Income225.68222.72187.77203.73206.14
      Total Income Growth (%)1.3318.61-7.84-1.17-8.17
      Total Expenses188.18183.18156.16205.82163.98
      Total Expenses Growth (%)2.7317.30-24.1325.520.05
      EBIT37.5039.5331.60-2.1042.16
      EBIT Growth (%)-5.1325.09--104.97-30.40
      Profit after Tax (PAT)23.8024.2620.70-9.1527.61
      PAT Growth (%)-1.8917.21--133.13-34.74
      EBIT Margin (%)16.6217.7516.83-1.0320.45
      Net Profit Margin (%)10.5510.8911.02-4.4913.39
      Basic EPS (₹)2.272.311.97-0.882.64
      Quarterly | AnnualDec 2024Sep 2024Jun 2024Mar 2024Dec 2023
      Total Income191.25191.00155.80172.28169.23
      Total Income Growth (%)0.1322.59-9.561.80-6.98
      Total Expenses160.82163.66128.48185.98138.92
      Total Expenses Growth (%)-1.7427.38-30.9233.883.15
      EBIT30.4427.3427.32-13.7030.31
      EBIT Growth (%)11.340.06--145.21-35.85
      Profit after Tax (PAT)21.0517.0419.42-11.4620.72
      PAT Growth (%)23.52-12.24--155.31-38.86
      EBIT Margin (%)15.9214.3117.54-7.9517.91
      Net Profit Margin (%)11.018.9212.46-6.6512.24
      Basic EPS (₹)2.001.631.85-1.111.99
      Quarterly | Annual FY 2024 FY 2023 FY 2022 FY 2021 FY 2020
      Total Revenue798.98769.37778.95597.43728.49
      Total Revenue Growth (%)3.85-1.2330.38-17.99-22.16
      Total Expenses652.91663.30651.19493.30586.15
      Total Expenses Growth (%)-1.571.8632.01-15.84-22.26
      Profit after Tax (PAT)75.4570.8615.0468.4997.27
      PAT Growth (%)6.49371.13-78.04-29.58-21.38
      Operating Profit Margin (%)19.8615.4917.7218.9921.74
      Net Profit Margin (%)9.799.422.0111.8614.11
      Basic EPS (₹)7.236.831.466.649.43
      Quarterly | Annual FY 2024 FY 2023 FY 2022 FY 2021 FY 2020
      Total Revenue638.96649.11668.98483.20478.95
      Total Revenue Growth (%)-1.56-2.9738.450.893.58
      Total Expenses527.62533.41545.33392.01357.24
      Total Expenses Growth (%)-1.09-2.1939.119.734.34
      Profit after Tax (PAT)50.6485.4892.6667.5092.33
      PAT Growth (%)-40.75-7.7537.28-26.9024.05
      Operating Profit Margin (%)19.3421.0120.1120.4829.03
      Net Profit Margin (%)8.3614.2814.5614.5020.89
      Basic EPS (₹)4.858.238.976.548.95

      All figures in Rs Cr, unless mentioned otherwise

      View Details
    • Annual FY 2024 FY 2023 FY 2022 FY 2021 FY 2020
      Total Assets1,213.871,156.851,108.751,076.791,029.02
      Total Assets Growth (%)4.934.342.974.6413.72
      Total Liabilities210.89239.43262.28248.88278.65
      Total Liabilities Growth (%)-11.92-8.715.39-10.6913.73
      Total Equity1,002.98917.42846.46827.91750.37
      Total Equity Growth (%)9.338.382.2410.3313.72
      Current Ratio (x)5.083.613.333.763.33
      Total Debt to Equity (x)0.090.110.130.120.14
      Contingent Liabilities56.8911.5922.7030.3114.33
      Annual FY 2024 FY 2023 FY 2022 FY 2021 FY 2020
      Total Assets1,152.551,139.691,079.96945.62855.10
      Total Assets Growth (%)1.135.5314.2110.5916.21
      Total Liabilities164.11202.69228.53189.97172.15
      Total Liabilities Growth (%)-19.03-11.3120.3010.3529.85
      Total Equity988.44937.00851.43755.65682.94
      Total Equity Growth (%)5.4910.0512.6810.6513.21
      Current Ratio (x)6.594.764.104.635.13
      Total Debt to Equity (x)0.070.080.100.090.10
      Contingent Liabilities55.8210.0921.8130.0614.33

      All figures in Rs Cr, unless mentioned otherwise

      View Details

    • Insights

      • Increase in Cash from Investing

        Company has used Rs 132.82 cr for investing activities which is an YoY increase of 1613.63%. (Source: Consolidated Financials)
      Annual FY 2024 FY 2023 FY 2022 FY 2021 FY 2020
      Net Cash flow from Operating Activities152.4534.31135.4863.9745.28
      Net Cash used in Investing Activities-132.82-7.75-92.98-46.99-48.95
      Net Cash flow from Financing Activities-20.89-24.94-23.73-20.80-3.83
      Net Cash Flow-1.423.028.85-2.210.30
      Closing Cash & Cash Equivalent23.5925.0121.9913.1315.34
      Closing Cash & Cash Equivalent Growth (%)-5.6613.7367.40-14.392.02
      Total Debt/ CFO (x)0.582.860.771.532.29
      Annual FY 2024 FY 2023 FY 2022 FY 2021 FY 2020
      Net Cash flow from Operating Activities125.9243.81114.0566.9758.03
      Net Cash used in Investing Activities-109.59-12.97-92.28-61.62-57.89
      Net Cash flow from Financing Activities-20.76-26.05-12.62-11.67-2.86
      Net Cash Flow-4.434.799.14-6.33-2.72
      Closing Cash & Cash Equivalent14.1718.6013.824.6711.03
      Closing Cash & Cash Equivalent Growth (%)-23.8034.65195.77-57.64-19.80
      Total Debt/ CFO (x)0.521.760.751.011.23

      All figures in Rs Cr, unless mentioned otherwise

      View Details
    • Annual FY 2024 FY 2023 FY 2022 FY 2021 FY 2020
      Return on Equity (%)7.808.011.838.4713.22
      Return on Capital Employed (%)14.5112.0815.1312.5518.81
      Return on Assets (%)6.216.121.356.369.45
      Interest Coverage Ratio (x)25.9513.0431.6023.0119.81
      Asset Turnover Ratio (x)0.650.530.590.4766.98
      Price to Earnings (x)15.6510.4853.1914.8810.70
      Price to Book (x)1.220.840.971.261.41
      EV/EBITDA (x)6.065.705.037.816.49
      EBITDA Margin (%)23.2817.9720.0421.9823.57
      Annual FY 2024 FY 2023 FY 2022 FY 2021 FY 2020
      Return on Equity (%)5.129.1210.888.9313.52
      Return on Capital Employed (%)11.3112.7414.4211.9217.59
      Return on Assets (%)4.397.508.587.1310.79
      Interest Coverage Ratio (x)24.2314.0132.8022.7419.38
      Asset Turnover Ratio (x)0.530.540.6349.2251.68
      Price to Earnings (x)23.318.698.6115.0811.26
      Price to Book (x)1.190.790.941.351.52
      EV/EBITDA (x)7.655.215.178.857.47
      EBITDA Margin (%)23.2323.5522.2823.4431.03

    Financial InsightsBliss GVS Pharma

    • Income (P&L)
    • Cash Flow

      • Employee & Interest Expense

        Company has spent less than 1% of its operating revenues towards interest expenses and 12.41% towards employee cost in the year ending Mar 31, 2024. (Source: Consolidated Financials)

      • Increase in Cash from Investing

        Company has used Rs 132.82 cr for investing activities which is an YoY increase of 1613.63%. (Source: Consolidated Financials)

    Do you find these insights useful?

    • hate it

    • meh

    • love it

    Bliss GVS Pharma Technicals

    • Stock doesn't have any Buy/Sell Signals.

    • 40%
      Positive Movement since
      1st Jan 2005 on basis
      58%
      Negative Movement since
      1st Jan 2005 on basis
      Exclude

    • Pivot Levels

      R1R2R3PIVOTS1S2S3
      Classic-------

      Average True Range

      5 DAYS14 DAYS28 DAYS
      ATR---

    Bliss GVS Pharma Peer Comparison

      • CHART
      • TABLE

      Insights

      • Stock Returns vs Nifty Smallcap 100

        Stock gave a 3 year return of 56.31% as compared to Nifty Smallcap 100 which gave a return of 72.97%. (as of last trading session)

      • Stock Returns vs Nifty Pharma

        Stock generated 56.31% return as compared to Nifty Pharma which gave investors 65.15% return over 3 year time period. (as of last trading session)

      • Choose from Peers

          Choose from Stocks

          • 1D
          • 1W
          • 1M
          • 3M
          • 6M
          • 1Y
          • 5Y
          Loading...

        • Insights

          • Stock Returns vs Nifty Smallcap 100

            Stock gave a 3 year return of 56.31% as compared to Nifty Smallcap 100 which gave a return of 72.97%. (as of last trading session)

          • Stock Returns vs Nifty Pharma

            Stock generated 56.31% return as compared to Nifty Pharma which gave investors 65.15% return over 3 year time period. (as of last trading session)

          Ratio Performance

          NAMEP/E (x)P/B (x)ROE %ROCE %ROA %Rev CAGR [3Yr]OPMNPMBasic EPSCurrent RatioTotal Debt/ Equity (x)Total Debt/ CFO (x)
          Bliss GVS Pharma19.771.177.8014.516.2110.0719.8610.597.235.080.090.58
          Solara Active Pharma-9.572.58-60.75-17.42-24.13-7.62-14.98-43.98-157.620.641.079.18
          SMS Pharma31.933.939.2912.754.817.9112.626.935.891.620.525.59
          Amrutanjan Health Care40.436.9115.5820.9112.258.2514.7410.6715.504.230.000.00
          Bajaj Healthcare-1,019.435.88-30.1017.71-10.95-10.0212.11-17.69-30.361.091.193.60
          Add More
          Annual Ratios (%)

          Choose from Peers

          • Syncom Form
          • Jagsonpal Pharm
          • Themis Medicare
          • Lincoln Pharma
          • Anuh Pharma

          Choose from Stocks

            See All Parameters

          Peers InsightsBliss GVS Pharma

            Do you find these insights useful?

            • hate it

            • meh

            • love it

            Bliss GVS Pharma Shareholding Pattern

            • Loading...
              Showing Bliss GVS Pharma Shareholding as on Mar 2025
              CategoryMar 2025Dec 2024Sep 2024Jun 2024
              Promoters35.2935.1034.8234.90
              Pledge0.000.000.000.00
              FII13.1813.5112.1213.24
              DII6.556.556.566.58
              Mutual Funds0.000.000.000.00
              Others44.9844.8446.5045.28
            • Showing Shareholding as on Mar 2025
              CategoryNo. of SharesPercentage% Change QoQ
              Promoters3,71,87,17435.29 %0.18
              Pledge00.00 %0.00
              FII1,38,87,91213.18 %-0.33
              DII69,03,7296.55 %0.00
              MF2,3740.00 %0.00
              Others4,73,91,45744.98 %0.14

            Bliss GVS Pharma MF Ownership

            MF Ownership as on 31 March 2025

            View all Mutual Fund Schemes
            Top Searches:
            Bliss GVS Pharma News Bliss GVS Pharma Quarterly Results Bliss GVS Pharma Dividend Bliss GVS Pharma Q1 ResultsBliss GVS Pharma Q2 ResultsBliss GVS Pharma Q3 ResultsBliss GVS Pharma Q4 Results

            Bliss GVS Pharma Corporate Actions

            • Meeting DateAnnounced onPurposeDetails
              May 12, 2025May 05, 2025Board MeetingAudited Results & Final Dividend
              Jan 28, 2025Jan 22, 2025Board MeetingQuarterly Results & Others
              Oct 24, 2024Oct 17, 2024Board MeetingQuarterly Results
              Jul 25, 2024May 03, 2024AGMBook closure from Jul 19, 2024 to Jul 25, 2024
              Jul 24, 2024Jul 18, 2024Board MeetingQuarterly Results
            • TypeDividendDividend per ShareEx-Dividend DateAnnounced on
              Final50%0.5Jul 18, 2024May 03, 2024
              Final50%0.5Jul 12, 2023May 11, 2023
              Final50%0.5Jun 20, 2022May 02, 2022
              Final50%0.5Sep 13, 2021May 11, 2021
              Final50%0.5Sep 17, 2020Jun 16, 2020
            • All TypesEx-DateRecord DateAnnounced onDetails
              BonusSep 26, 2008Sep 30, 2008Jul 29, 2008Bonus Ratio: 3 share(s) for every 5 shares held
              SplitsMar 11, 2008Mar 18, 2008Jan 18, 2008Split: Old FV10.0| New FV:1.0
              BonusSep 28, 2005Oct 01, 2005Jul 25, 2005Bonus Ratio: 2 share(s) for every 5 shares held

            About Bliss GVS Pharma

            Bliss GVS Pharma Ltd., incorporated in the year 1984, is a Small Cap company (having a market cap of Rs 1,178.46 Crore) operating in Pharmaceuticals sector. Bliss GVS Pharma Ltd. key Products/Revenue Segments include Pharmaceuticals, Export Incentives and Sale of services for the year ending 31-Mar-2024. Show More

            • Executives

            • Auditors

            • SR

              S R Vaidya

              Chairman & Ind.Director
              GH

              Gagan Harsh Sharma

              Managing Director
              SV

              Shruti Vishal Rao

              Whole Time Director
              VG

              Vibha Gagan Sharma

              Whole Time Director
              Show More
            • Kalyaniwalla & Mistry LLP

            Industry

            Pharma - Indian

            Key Indices Listed on

            BSE SmallCap, BSE Healthcare, BSE AllCap, + 1 more

            Address

            102, Hyde Park,Saki Vihar Road,Mumbai, Maharashtra - 400072

            Contact

            [email protected]

            http://www.blissgvs.com

            More Details

            FAQs about Bliss GVS Pharma share

            • 1. What's the Bliss GVS Pharma share price today?
              As on 09 May, 2025, 03:59 PM IST Bliss GVS Pharma share price is down by 0.21% basis the previous closing price of Rs 115.37. Bliss GVS Pharma share price is Rs 111.84. Return Performance of Bliss GVS Pharma Shares:
              • 1 Week: Bliss GVS Pharma share price moved down by 5.16%
              • 1 Month: Bliss GVS Pharma share price moved down by 3.93%
              • 6 Month: Bliss GVS Pharma share price moved down by 10.00%
            • 2. Which are the key peers to Bliss GVS Pharma?
              Top 10 Peers for Bliss GVS Pharma are Lincoln Pharmaceuticals Ltd., Syncom Formulation (India) Ltd., Jagsonpal Pharmaceuticals Ltd., SMS Pharmaceuticals Ltd., Amrutanjan Health Care Ltd., NGL Fine - Chem Ltd., Themis Medicare Ltd., Solara Active Pharma Sciences Ltd., Bajaj Healthcare Ltd. and Anuh Pharma Ltd.
            • 3. What dividend is Bliss GVS Pharma giving?
              An equity Final dividend of Rs 0.5 per share was declared by Bliss GVS Pharma Ltd. on 03 May 2024. So, company has declared a dividend of 50% on face value of Rs 1 per share. The ex dividend date was 18 Jul 2024.
            • 4. What is 52 week high/low of Bliss GVS Pharma share price?
              Bliss GVS Pharma share price saw a 52 week high of Rs 185.50 and 52 week low of Rs 92.15.
            • 5. What are the key metrics to analyse Bliss GVS Pharma Share Price?
              Key Metrics for Bliss GVS Pharma are:
              • PE Ratio of Bliss GVS Pharma is 19.77
              • Price/Sales ratio of Bliss GVS Pharma is 1.53
              • Price to Book ratio of Bliss GVS Pharma is 1.18
            • 6. Who's the owner of Bliss GVS Pharma?
              Following are the key changes to Bliss GVS Pharma shareholding:
              • Promoter holding has gone up from 34.9 (30 Jun 2024) to 35.29 (31 Mar 2025)
              • Domestic Institutional Investors holding have gone down from 6.58 (30 Jun 2024) to 6.55 (31 Mar 2025)
              • Foreign Institutional Investors holding have gone down from 13.24 (30 Jun 2024) to 13.18 (31 Mar 2025)
              • Other investor holding have gone down from 45.28 (30 Jun 2024) to 44.98 (31 Mar 2025)
            • 7. What is the CAGR of Bliss GVS Pharma?
              The CAGR of Bliss GVS Pharma is 7.48.
            • 8. What are the Bliss GVS Pharma quarterly results?
              On Consoldiated basis, Bliss GVS Pharma reported a total income and profit of Rs 225.68 Cr and Rs 23.80 respectively for quarter ending 2024-12-31. Total Income and profit for the year ending 2024-03-31 was Rs 798.98 Cr and Rs 75.45 Cr.
            • 9. What is the market cap of Bliss GVS Pharma?
              Within the Pharmaceuticals sector, Bliss GVS Pharma stock has a market cap rank of 74. Bliss GVS Pharma has a market cap of Rs 1,178.46 Cr.
            • 10. Who's the chairman of Bliss GVS Pharma?
              S R Vaidya is the Chairman & Ind.Director of Bliss GVS Pharma
            • 11. What are the returns for Bliss GVS Pharma share?
              Return Performance of Bliss GVS Pharma Shares:
              • 1 Week: Bliss GVS Pharma share price moved down by 5.16%
              • 1 Month: Bliss GVS Pharma share price moved down by 3.93%
              • 6 Month: Bliss GVS Pharma share price moved down by 10.00%
            • 12. What is the PE & PB ratio of Bliss GVS Pharma?
              The PE ratio of Bliss GVS Pharma stands at 19.81, while the PB ratio is 1.17.

            Trending in Markets

            Top Gainers As on 03:59 PM | 09 May 2025

            KPR Mill1,306.25
            276.30 (26.83%)
            R R Kabel1,234.80
            211.00 (20.61%)
            CCL Products723.35
            123.25 (20.54%)
            Welspun India146.90
            21.33 (16.99%)
            YES Bank20.02
            2.32 (13.11%)

            Top Losers As on 03:56 PM | 09 May 2025

            Jindal Saw201.68
            -43.75 (-17.83%)
            Sonata Software365.70
            -54.95 (-13.06%)
            Bank of Baroda220.09
            -28.52 (-11.47%)
            Godrej Properties2,000.50
            -248.80 (-11.06%)
            Indian Hotels718.75
            -81.75 (-10.21%)

            DATA SOURCES: TickerPlant (for live BSE/NSE quotes service) and Dion Global Solutions Ltd. (for corporate data, historical price & volume, F&O data). Sensex & BSE Quotes and Nifty & NSE Quotes are real-time and licensed from BSE and NSE respectively. All timestamps are reflected in IST (Indian Standard Time).

            DISCLAIMER: Any and all content on this website including tools/analysis is provided to you only for convenience and on an “as-is, as- available” basis without representation and warranties of any kind. The content and any output of such tools/analysis is for informational purposes only and should not be relied upon or construed as an investment advice or guarantee for any specific performance/returns advice or considered as recommendation for the purchase or sale of any security or investment. You are advised to exercise caution, discretion and independent judgment with regards to the same and seek advice from professionals and certified experts before taking any decisions.

            By using this site, you agree to the Terms of Service and Privacy Policy.

            Business News›Markets›Stocks›Stock Price Quotes›Bliss GVS Pharma Share Price
            The Economic Times
            BrowseCompanies:
            OSZAR »